Revance Therapeutics (RVNC)
(Delayed Data from NSDQ)
$5.81 USD
-0.04 (-0.68%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.83 +0.02 (0.34%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth NA Momentum NA VGM
Brokerage Reports
0 items in cart
Revance Therapeutics, Inc. [RVNC]
Reports for Purchase
Showing records 1 - 20 ( 61 total )
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Revance Merges With Crown Laboratories; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Daxxify Shows Some Positive Signs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Daxxify Gains Share But Misses Expectations, Ramp to Guidance Remains a Concern
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hugel Wins Approval But Impact on Neurotoxin Market Likely Small For the Foreseeable Future
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Strategy Gets Some Further Refinements as Revance Leans Into Pricing; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Steep Ramp for Daxxify Gives Us Some Pause; Reiterate Buy Though PT Down to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Daxxify Falls Flat in 4Q, Clouding Guide for 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Financial Update for 3Q; Reiterate Buy and $15 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Duration Message Diluted With Price Cut; Lowering Estimates; Price Target Down to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Loss of Momentum Leads to Strategic Shift; Quick Thoughts After Revance Cuts Price on Daxxify
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Daxxify Receives Green Light to Enter the Therapeutic Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Daxxify Does Not Disappoint; PT Adjusted to $41; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Strong Quarter for Daxxi as Broader Launch Begins; PT Up to $48; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Revance Therapeutics'' President; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
What''s the Early Buzz on Social Media for Daxxify? Raise PT to $42; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
"PrevU" Offers a Preview of Things; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Daxxify Moves Ahead on All Fronts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Revance''s sBLA for Daxxify Submitted to the FDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Revance Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Daxi Gets Approved and a Cool New Name; PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D